Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes in Ovarian Carcinoma

Ovarian cancer is one of the most common gynecologic malignancies (Suh et al., 2012). Because of rare specific symptoms and lack of feasible screening methods, more than two-thirds of patients with ovarian cancer are diagnosed at advanced-stage disease, which leads to poor prognosis. Taxanes and platinum-based chemotherapy after surgery has been established as the first line treatment by previous randomized controlled trials (Ozols et al., 2003; Suh et al., 2012). However, cisplatin has nephrotoxicity, gastointestinal toxicity and neurotoxicity. Myelotoxicity, especially thrombocytopenia has been found to be the dose limiting toxicity of carboplatin. Especially in ovarian cancer, carboplatin appears to have equivalent activity to cisplatin. Besides, cisplatin and carboplatin are crossresistant (Alberts et al., 1989; Kim et al., 2011). Hence, new effective platinum-based chemotherapeutic agent with less toxicity and non-cross-resistance is needed for the treatment of ovarian cancer. Lobaplatin (1, 2-diamminomethylcyclobutaneplatinum (II)-lactate), one of the third-generation platinum